Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Tallac Therapeutics (Formerly Tollnine)

Request full access

Rapidly advancing the company’s lead programs in cancer toward clinical trials in multiple indications

Burlingame, United StatesFounded 2018Biotech & Life Sciences

About Tallac Therapeutics (Formerly Tollnine)

Tallac Therapeutics, operating as a privately held biopharmaceutical firm since its establishment in 2018, concentrates on developing immunotherapies to combat cancer. The company, formerly known as Tollnine, was co-founded by Dr. Hong I. Wan, Dr. Corey Goodman, Dr. Jaume Pons, and Dr. Curt Bradshaw. Dr. Wan, who also serves as President and CEO, brings over two decades of drug development experience from leadership roles at Pfizer, Wyeth Research, and as a founding member of ALX Oncology. Her academic background includes a Ph.D. in molecular and cell biology from the University of California, Berkeley, and a degree in biochemical sciences from Harvard University.

The company's core technology is its Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform. This platform develops next-generation antibody drug conjugates (ADCs) that deliver a potent Toll-like receptor 9 (TLR9) agonist, known as T-CpG, directly to the tumor microenvironment. By doing so, it aims to trigger both innate and adaptive immune responses for a more robust and durable anti-cancer effect. The business model centers on the discovery, preclinical development, and clinical advancement of its pipeline candidates to address unmet needs in oncology for patients with solid tumor malignancies. Tallac's approach allows for the systemic delivery of these therapies, a method designed to overcome resistance seen in some existing immunotherapies.

Tallac's lead product candidate, TAC-001, is a first-in-class TRAAC molecule that entered a Phase 1/2 clinical trial for patients with advanced or metastatic solid tumors after receiving FDA clearance in May 2022. TAC-001 conjugates a TLR9 agonist to an antibody that targets CD22, a receptor found on B cells, thereby activating these immune cells to fight the cancer. Preclinical data has shown that TAC-001 can lead to complete tumor eradication and immune memory in checkpoint-resistant models. The company has secured significant financial backing, including a Series A financing round that raised $62 million in December 2020, with investors such as venBio Partners, Morningside Venture, and Lightstone Ventures. This funding supports the advancement of its pipeline, which includes several other TRAAC molecules in discovery and development.

Source: Dealroom company data

At a glance

Status
Operational
Employees
13
Open positions
None listed
Dealroom signal
62.4/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
DEBTDebt Aug 2023 $15M — Horizon Technology Finance Corporation ↗
SERIES AOther financing Dec 2020 $62M $248M Matrix Partners China · Lightstone Ventures · Morningside · venBio Partners —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Tallac Therapeutics (Formerly Tollnine) website traffic

Latest recorded traffic for Tallac Therapeutics (Formerly Tollnine) is 1.6K monthly website visits, down 33.3% over the last three months. Tallac Therapeutics (Formerly Tollnine)'s team declined 18.8% over the past year.

Latest monthly visits1.6K 3-month web change-33.3% 1-year team growth-18.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Tallac Therapeutics (Formerly Tollnine) in the Burlingame ecosystem

Live from Dealroom

The Tallac Therapeutics (Formerly Tollnine) office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

Series B and later1 investor entered at this stage

  • Horizon Technology Finance Corporation
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Tallac Therapeutics (Formerly Tollnine) on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Tallac Therapeutics (Formerly Tollnine)’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.